Johnson & Johnson Can’t Be More Risky. Option Traders Sell It

 Johnson & Johnson Can't Be More Risky. Option Traders Sell It

In today’s session Johnson & Johnson (JNJ) recorded an unusually high (1,556) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious JNJ decrease. With 1,556 contracts traded and 12774 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: JNJ161216P00111000 closed last at: $0.71 or 22.4% up. About 1.71 million shares traded hands. Johnson & Johnson (NYSE:JNJ) has declined 1.05% since April 28, 2016 and is downtrending. It has underperformed by 6.97% the S&P500.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 24 before the open. They expect $1.56 EPS, up 8.33% or $0.12 from last year’s $1.44 per share. JNJ’s profit will be $4.20B for 17.82 P/E if the $1.56 EPS becomes a reality. After $1.68 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Out of 13 analysts covering Johnson & Johnson (NYSE:JNJ), 6 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 46% are positive. $145 is the highest target while $90 is the lowest. The $116.69 average target is 4.92% above today’s ($111.22) stock price. Johnson & Johnson has been the topic of 39 analyst reports since August 7, 2015 according to StockzIntelligence Inc. As per Friday, December 18, the company rating was initiated by Atlantic Securities. The rating was maintained by UBS with “Buy” on Wednesday, October 19. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by Deutsche Bank on Tuesday, September 29. The firm has “Buy” rating given on Tuesday, September 22 by UBS. The rating was maintained by Jefferies on Tuesday, September 13 with “Hold”. The stock has “Outperform” rating given by RBC Capital Markets on Wednesday, July 20. As per Tuesday, March 15, the company rating was maintained by Jefferies. Goldman Sachs upgraded the shares of JNJ in a report on Monday, March 14 to “Neutral” rating. Jefferies maintained Johnson & Johnson (NYSE:JNJ) rating on Thursday, August 4. Jefferies has “Hold” rating and $119 price target. The rating was maintained by Jefferies on Thursday, July 14 with “Hold”.

According to Zacks Investment Research, “Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women’s health fields, nutritional and over-the-counter pharmaceutical products. The company’s Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women’s health products. Johnson & Johnson is based in New Brunswick, New Jersey.”

Insitutional Activity: The institutional sentiment decreased to 0.82 in 2016 Q2. Its down 0.04, from 0.86 in 2016Q1. The ratio dropped, as 49 funds sold all Johnson & Johnson shares owned while 890 reduced positions. 103 funds bought stakes while 703 increased positions. They now own 1.75 billion shares or 5.01% less from 1.84 billion shares in 2016Q1.
Nichols Asset Lc last reported 2.05% of its portfolio in the stock. Glenmede Trust Na accumulated 2.59 million shares or 1.9% of the stock. Iron Financial Limited Com holds 0.72% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 4,605 shares. South State accumulated 2.58% or 141,751 shares. Stelac Advisory Services Llc holds 0.09% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 2,370 shares. Palladium Prns Ltd Liability Corporation has 2.72% invested in the company for 246,594 shares. Sunbelt Securities Inc owns 6,441 shares or 0% of their US portfolio. New England And Management accumulated 2.64% or 25,280 shares. Phocas Finance Corp last reported 0.5% of its portfolio in the stock. The Florida-based Daniel Devine Communication has invested 3.96% in Johnson & Johnson (NYSE:JNJ). Page Arthur B holds 5.74% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 47,099 shares. Glg Ptnrs Limited Partnership holds 529 shares or 0% of its portfolio. Meridian Counsel last reported 2.18% of its portfolio in the stock. Counselors holds 1.11% or 153,574 shares in its portfolio. Mitchell Sinkler & Starr Pa holds 28,392 shares or 4.7% of its portfolio.

Insider Transactions: Since June 7, 2016, the stock had 1 buy, and 4 insider sales for $6.89 million net activity. $347,381 worth of Johnson & Johnson (NYSE:JNJ) shares were sold by Kapusta Ronald A. On Friday, October 21 PRINCE CHARLES bought $99,846 worth of the stock or 875 shares. The insider Pruden Gary J sold $1.13M. Shares for $5.14 million were sold by Caruso Dominic J.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The company has a market cap of $299.40 billion. The Company’s divisions include Consumer, Pharmaceutical and Medical Devices. It has a 19.49 P/E ratio. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

JNJ Company Profile

Johnson & Johnson, incorporated on November 10, 1887, is a holding company. The Firm and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s divisions include Consumer, Pharmaceutical and Medical Devices. The Company’s primary focus is on products related to human health and well-being. The Company’s subsidiaries operate over 120 manufacturing facilities. The Company’s research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom. The Firm has over 250 operating companies, which conduct business around the world.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: which released: “Johnson & Johnson Has Its Eye on Actelion” on November 25, 2016, also with their article: “J&J raises Actelion takeover pressure with higher price: source” published on November 29, 2016, published: “Johnson & Johnson Throws Caution to the Wind With a Large Bid for Actelion” on November 30, 2016. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: and their article: “Analysts’ Actions — Goldman Sachs, Johnson & Johnson, Pfizer and More” published on November 29, 2016 as well as‘s news article titled: “Johnson & Johnson: Durable Dividend Payer With Growth” with publication date: November 25, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment